Axon Enterprise, Inc $AXON Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. decreased its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 34.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 73,418 shares of the biotechnology company’s stock after selling 38,928 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Axon Enterprise were worth $52,688,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of AXON. Newbridge Financial Services Group Inc. boosted its stake in shares of Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after buying an additional 14 shares during the period. Vicus Capital increased its stake in shares of Axon Enterprise by 3.7% during the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after buying an additional 14 shares during the period. Evergreen Capital Management LLC raised its holdings in Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after acquiring an additional 15 shares in the last quarter. Blue Trust Inc. raised its holdings in Axon Enterprise by 2.5% in the third quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock valued at $463,000 after acquiring an additional 16 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC lifted its stake in Axon Enterprise by 5.4% in the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 16 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Down 3.5%

Shares of NASDAQ:AXON opened at $499.40 on Friday. The firm has a 50 day simple moving average of $532.43 and a 200-day simple moving average of $612.29. Axon Enterprise, Inc has a twelve month low of $396.41 and a twelve month high of $885.91. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $40.15 billion, a PE ratio of 328.55, a P/E/G ratio of 11.05 and a beta of 1.46.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. During the same period last year, the firm posted $2.08 EPS. The company’s revenue was up 38.5% on a year-over-year basis. On average, equities analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total value of $5,002,400.00. Following the completion of the sale, the chief executive officer directly owned 3,090,997 shares of the company’s stock, valued at approximately $1,546,240,339.28. The trade was a 0.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Isaiah Fields sold 2,000 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the sale, the insider directly owned 55,588 shares of the company’s stock, valued at approximately $29,740,135.88. This trade represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 24,634 shares of company stock worth $13,803,095 over the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Wall Street Analysts Forecast Growth

AXON has been the subject of several analyst reports. Barclays lowered their price target on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday, December 29th. Royal Bank Of Canada lowered their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. UBS Group dropped their target price on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Finally, Citigroup reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.